Publications by authors named "Oscar Otero Garcia"
Echocardiographic Phenotype in Severe Aortic Stenosis With and Without Transthyretin Cardiac Amyloidosis: The AMY-TAVI Study.
Eur Heart J Cardiovasc Imaging
October 2024
Aim: The relative apical sparing pattern of left ventricular (LV) longitudinal strain (RELAPS]>1) has been described as a typical sign of cardiac amyloidosis (CA). The objective was to validate this pattern in concomitant CA and aortic stenosis (AS) and to identify new echocardiographic variables suggestive of CA in the presence of AS.
Methods And Results: 324 consecutive patients (age 81.
The promising results obtained in the PARADIGM-HF trial prompted the approval of sacubitril/valsartan (SAC/VAL) as a first-in-class treatment for heart failure with reduced ejection fraction (HFrEF) patients. The effect of SAC/VAL treatment was also studied in patients with heart failure with preserved ejection fraction (HFpEF) and, although improvements in New York Heart Association (NYHA) class, HF hospitalizations, and cardiovascular deaths were observed, these results were not so promising. However, the demand for HFpEF therapies led to the approval of SAC/VAL as an alternative treatment, although further studies are needed.
View Article and Find Full Text PDFAims: To investigate the association between the elapsed time to cardiology care following a primary care physician (PCP) referral and 1 year outcomes among patients with heart failure (HF).
Methods: Data from electronic medical records at our institution encompassing all PCP referrals to cardiology consultation from 2010 to 2021 (N = 68 518) were analysed. Of these, 6379 patients had a prior diagnosis of HF.
Article Synopsis
- The study investigated the effects of long-term use of RAAS inhibitors on hypertensive patients hospitalized with COVID-19, finding that nearly 74% of these patients were using such medications prior to hospitalization.
- Results showed that hypertensive patients had a higher mortality rate; however, those on RAAS inhibitors had a lower risk of death, and the use of these medications appeared to provide a protective benefit.
- The overall conclusion is that RAAS inhibitors may be beneficial for hypertensive COVID-19 patients, and continued use during hospitalization likely does not worsen outcomes, supported by a separate meta-analysis.
Article Synopsis
- * Out of 2004 patients studied, those with improved or stable kidney function after one year experienced significantly lower rates of major adverse cardiovascular events and all-cause mortality.
- * The findings suggest that monitoring and improving renal function in these patients is crucial for better long-term health outcomes following STEMI.
Background: In elderly patients with non-ST elevation acute coronary syndrome (NSTEACS), while routine invasive management is established in high-risk NSTEACS patients, there is still uncertainty regarding the optimal timing of the procedure.
Methods: This study analyzes the association of early coronary angiography with all-cause mortality, cardiovascular mortality, heart failure (HF) hospitalization, and major adverse cardiovascular events (MACE) in patients older than 75 years old with NSTEACS. This retrospective observational study included 7811 consecutive NSTEACS patients who were examined between the years 2003 and 2017 at two Spanish university hospitals.
Article Synopsis
- The study analyzes cardiovascular outcomes in patients with diabetes mellitus who are experiencing non-ST elevation acute coronary syndrome (NSTEACS) and evaluates the effectiveness of two risk assessment scores: GRACE and PRECISE-DAPT.
- A total of 7,415 patients were included, with 28% having diabetes; findings revealed diabetic patients were generally older and had higher initial risk scores, with differences in treatment approaches observed.
- The PRECISE-DAPT score effectively predicted mortality and adverse cardiovascular events in diabetic patients, while the GRACE score performed worse over the long term for these individuals.
Aims: Left ventricular ejection fraction (LVEF) recovery after an ST-segment elevation myocardial infarction (STEMI) identifies a group of patients with a better prognosis. However, the association between long-term outcomes and LVEF recovery among patients with STEMI undergoing primary percutaneous coronary intervention (PCI) has not yet been well investigated. Our study aims to detect differences in long-term all-cause and cardiovascular mortality between patients who recover LVEF at 1-year post-PCI and those who do not, and search for predictors of LVEF recovery.
View Article and Find Full Text PDFArticle Synopsis
- * Out of 849 patients, nearly half were hypertensive; those on RAAS inhibitors before and during hospitalization had lower mortality rates than those not on these medications.
- * The analysis suggests that RAAS inhibitors may provide protective benefits for hypertensive COVID-19 patients, indicating that continuing these medications during treatment may not worsen outcomes.
Deterioration is sometimes unexpected in SARS-CoV2 infection. The aim of our study is to establish laboratory predictors of mortality in COVID-19 disease which can help to identify high risk patients. All patients admitted to hospital due to Covid-19 disease were included.
View Article and Find Full Text PDFArticle Synopsis
- - The study evaluated the impact of heart disease (HD) and cardiovascular medications on COVID-19 hospitalized patients, revealing that those with HD had higher mortality rates compared to those without (35.4% vs. 18.2%).
- - Among 859 patients, diabetes was particularly linked to increased risk of death, while common cardiovascular medications did not worsen patient outcomes; however, statins were associated with lower mortality rates.
- - The occurrence of cardiovascular events during hospitalization was linked to worse overall outcomes, with a mortality rate of 31.8% in patients who experienced such events compared to 19.3% in those who did not.
Prognostic benefit from an early invasive strategy in patients with non-ST elevation acute coronary syndrome (NSTEACS): evaluation of the new risk stratification in the NSTEACS European guidelines.
Clin Res Cardiol
September 2021
Objectives: The objective of our work is to evaluate the prognostic benefit of an early invasive strategy in patients with high-risk NSTACS according to the recommendations of the 2020 clinical practice guidelines during long-term follow-up.
Methods: This retrospective observational study included 6454 consecutive NSTEACS patients. We analyze the effects of early coronary angiography (< 24 h) in patients with: (a) GRACE risk score > 140 and (b) patients with "established NSTEMI" (non ST-segment elevation myocardial infarction defined by an increase in troponins) or dynamic ST-T-segment changes with a GRACE risk score < 140.
Background: Limited data are available regarding change in the nutritional status after transcatheter aortic valve replacement (TAVR). This study evaluated the prognostic impact of the change in the geriatric nutritional risk index following TAVR.
Methods: TAVR patients were analyzed in a prospective and observational study.
Background: Healthcare systems are under prominent stress due to the COVID-19 pandemic. A fast and simple triage is mandatory to screen patients who will benefit from early hospitalization, from those that can be managed as outpatients. There is a lack of all-comers scores, and no score has been proposed for western-world population.
View Article and Find Full Text PDFObjective: The aim of this work is to assess the relationship between significant paravalvular leak (SPL) after transcatheter aortic valve implantation (TAVI) on anaemia and their impact on prognosis.
Methods: Observational analytic study developed at two university hospitals, including all consecutive patients who underwent TAVI during a 10-year period (2009 to 2018). A logistic regression model was created to determine independent predictors of anaemia at 3 months.
Article Synopsis
- COVID-19 is a global pandemic, and researchers aimed to understand if prior use of ACE inhibitors (ACEI) or angiotensin receptor blockers (ARB) affects the outcomes for patients diagnosed with the virus.
- A retrospective study of nearly 1,000 COVID-19 patients found that those on ACEI/ARB drugs showed no significant differences in mortality, hospitalization, or severe cardiovascular events.
- The study concludes that continuing ACEI/ARB treatment in COVID-19 patients is supported by existing guidelines, as it doesn't negatively impact their health outcomes.
Introduction And Objectives: Coronavirus disease (COVID-19) has been designated a global pandemic by the World Health Organization. It is unclear whether previous treatment with angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) affects the prognosis of COVID-19 patients. The aim of this study was to evaluate the clinical implications of previous treatment with ACEI/ARB on the prognosis of patients with COVID-19 infection.
View Article and Find Full Text PDF